Single Ascending Doses of BIIB063 in Healthy Volunteers
Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
West Yorkshire
-
Leeds, West Yorkshire, Vereinigtes Königreich, LD2 9LH
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
- Must have a body mass index between 18 and 30 kg/m2, inclusive.
- Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.
Key Exclusion Criteria:
- History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
- History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
- Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
- History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
- History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
- Personal history of thromboembolic events
- Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
- Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
- Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
- Blood donation (1 unit or more) within 3 months prior to randomization.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: SC Dose
Single SC dose or matching placebo
|
Single ascending IV dose
Einzelne Dosis
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant laboratory assessment abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant Vital sign abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant physical examination abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for tetanus
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for diphtheria
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for pneumococcus
Zeitfenster: Up to week 12
|
Up to week 12
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with positive serum anti-BIIB063 antibodies
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Zeitfenster: Up to 12 weeks
|
Up to 12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 234HV101
- 2015-001283-18 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .